{"DataElement":{"publicId":"3228154","version":"1","preferredName":"Laboratory Procedure Topoisomerase II Alpha Tumor Marker Outcome Status","preferredDefinition":"the status of any procedure that involves testing or manipulating a sample of blood, urine, or other body substance in a laboratory setting for topoisomerase II alpha, a homodimer that controls DNA topology by transient ATP-dependent double-strand breakage and rejoining and is also associated with the Pol II holoenzyme and required for chromatin-dependent co-activation and productive RNA synthesis, as a tumor marker for breast cancer.","longName":"3228125v1.0:3228126v1.0","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"3228125","version":"1","preferredName":"Laboratory Procedure Topoisomerase II Alpha Tumor Marker Outcome","preferredDefinition":"information related to the result of any procedure that involves testing or manipulating a sample of blood, urine, or other body substance in a laboratory setting for topoisomerase II alpha, a homodimer that controls DNA topology by transient ATP-dependent double-strand breakage and rejoining and is also associated with the Pol II holoenzyme and required for chromatin-dependent co-activation and productive RNA synthesis, as a tumor marker for breast cancer.","longName":"2543047v1.0:3228123v1.0","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2543047","version":"1","preferredName":"Test","preferredDefinition":"A procedure for critical evaluation; a means of determining the presence, quality, or truth of something.","longName":"C25294","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Laboratory Procedure","conceptCode":"C25294","definition":"Any procedure that involves testing or manipulating a sample of blood, urine, or other body substance in a laboratory setting.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"2262D258-9F2F-4D98-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-11-16","endDate":null,"createdBy":"IVERSONJ","dateCreated":"2006-11-16","modifiedBy":"ONEDATA","dateModified":"2006-11-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"3228123","version":"1","preferredName":"Topoisomerase II Alpha Tumor Marker Outcome","preferredDefinition":"Involved in chromosome condensation and segregation, topoisomerase II alpha is a homodimer that controls DNA topology by transient ATP-dependent double-strand breakage and rejoining.  Topoisomerase II alpha is also associated with the Pol II holoenzyme and required for chromatin-dependent co-activation and productive RNA synthesis.  (from OMIM 126430 and NCI):A substance sometimes found in an increased amount in the blood, other body fluids, or tissues and which may mean that a certain type of cancer is in the body. Examples of tumor markers include CA 125 (ovarian cancer), CA 15-3 (breast cancer), CEA (ovarian, lung, breast, pancreas, and gastrointestinal tract cancers), and PSA (prostate cancer). Also called biomarker.:Outcome; a phenomenon that follows and is caused by some previous phenomenon.","longName":"C17801:C17220:C20200","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"DNA Topoisomerase 2-Alpha","conceptCode":"C17801","definition":"DNA topoisomerase 2-alpha (1531 aa, ~174 kDa) is encoded by the human TOP2A gene. This protein is involved in the modulation of DNA topology.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Tumor Marker","conceptCode":"C17220","definition":"A substance present in or produced by a tumor or by the host, that can be used for differentiating neoplastic from normal tissue based on measurements in body fluids, secretions, cells, and/or tissues. Markers are used in diagnosis, staging and prognosis of cancer, provide an estimation of tumor burden, and serve for monitoring effects of therapy, detecting recurrence, localization of tumors, and screening in general populations.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Outcome","conceptCode":"C20200","definition":"The result of an action.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A133B408-79E0-58A1-E040-BB89AD4361FB","latestVersionIndicator":"Yes","beginDate":"2011-04-18","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-04-18","modifiedBy":"ONEDATA","dateModified":"2011-04-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A133B408-79F1-58A1-E040-BB89AD4361FB","latestVersionIndicator":"Yes","beginDate":"2011-04-18","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-04-18","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3228126","version":"1","preferredName":"Topoisomerase II Alpha Tumor Marker Status","preferredDefinition":"A condition or state Topoisomerase II Alpha Tumor Marker at a particular time.","longName":"3228126v1.0","context":"CTEP","contextVersion":"2.31","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"25","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Positive/over-expressing","valueDescription":"Overexpression","ValueMeaning":{"publicId":"3228127","version":"1","preferredName":"Overexpression","longName":"3228127","preferredDefinition":"Overexpression is the biosynthesis of new mRNA transcripts or protein product of a gene at a rate, or to an amount, that is greater than normal under similar cirucmstances.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Overexpression","conceptCode":"C45729","definition":"Overexpression is the biosynthesis of new mRNA transcripts or protein product of a gene at a rate, or to an amount, that is greater than normal under similar cirucmstances.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A134A561-CF15-CB3D-E040-BB89AD434393","latestVersionIndicator":"Yes","beginDate":"2011-04-18","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-04-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A134A561-CF2E-CB3D-E040-BB89AD434393","beginDate":"2011-04-18","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-04-18","modifiedBy":"ONEDATA","dateModified":"2011-04-18","deletedIndicator":"No"},{"value":"Negative/normal","valueDescription":"Normal","ValueMeaning":{"publicId":"2567281","version":"1","preferredName":"Normal","longName":"2567281","preferredDefinition":"Being approximately average or within certain limits; conforming with or constituting a norm or standard or level or type or social norm.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Normal","conceptCode":"C14165","definition":"Being approximately average or within certain limits; conforming with or constituting a norm or standard or level or type or social norm.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D3DE-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-11-14","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-11-14","modifiedBy":"GDEEN","dateModified":"2024-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A134A561-CF42-CB3D-E040-BB89AD434393","beginDate":"2011-04-18","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-04-18","modifiedBy":"ONEDATA","dateModified":"2011-04-18","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2404650","version":"1","preferredName":"Status","preferredDefinition":"A condition or state at a particular time.","longName":"C25688","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Status","conceptCode":"C25688","definition":"A condition or state at a particular time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"005AD6E5-057F-6A35-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-09-09","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-09-09","modifiedBy":"ONEDATA","dateModified":"2005-09-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A134A561-CEFE-CB3D-E040-BB89AD434393","latestVersionIndicator":"Yes","beginDate":"2011-04-18","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-04-18","modifiedBy":"COOPERM","dateModified":"2017-02-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008589","version":"2","longName":"Type of Category","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811957","version":"1","longName":"Labs","context":"CTEP"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Summary of Topoisomerase II a","type":"Preferred Question Text","description":"Summary of Topoisomerase II alpha (TOPO II) status of primary tumour","url":null,"context":"CTEP"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A134A561-CF95-CB3D-E040-BB89AD434393","latestVersionIndicator":"Yes","beginDate":"2011-04-18","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-04-18","modifiedBy":"CAMPBELB","dateModified":"2011-04-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}